Loading news...
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The
MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments under certain conditions is fair to Generation Bio shareholders. Halper Sadeh encourages Generation Bio shareholders to click here to learn more about their legal rights and options or contact Danie.
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results.
Generation Bio (NASDAQ: GBIO - Get Free Report) and Nuvation Bio (NYSE: NUVB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends. Institutional and Insider Ownership 95.2% of Generation
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company's Board of Directors.
Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago.
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune diseases • Company is evaluating strategic alternatives to maximize value of its delivery system and potential therapeutics for T cell-driven autoimmune diseases for shareholders • Cash balance of $141.4M as of June 30, 2025 • Recent litigation settlement extinguishes lease liability CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced new data demonstrating that its cell-targeted lipid nanoparticle (ctLNP) system selectively delivered siRNA to T cells in non-human primates, reinforcing the company's belief that its ctLNP has the ability to deliver diverse genetic medicine payloads to multiple new cell types.
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company's common stock (“Reverse Stock Split”), effective at 5:00 pm Eastern Time on July 21, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 4, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company's 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee's entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Squarepoint Ops LLC purchased a new position in Generation Bio Co. (NASDAQ:GBIO – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,628 shares of the company’s stock, valued at approximately $70,000. Squarepoint Ops LLC owned approximately 0.10% of Generation Bio as of its most recent SEC filing. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in shares of Generation Bio in the 4th quarter valued at approximately $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $77,000. Millennium Management LLC acquired a new position in shares of Generation Bio in the 4th quarter worth approximately $97,000. Deutsche Bank AG raised its holdings in shares of Generation Bio by 688.7% in the 4th quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock worth $195,000 after buying an additional 160,822 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 74.9% in the 4th quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock worth $316,000 after buying an additional 127,513 shares in the last quarter. Institutional investors own 95.22% of the company’s stock. Analysts Set New Price Targets A number of equities analysts have recently issued reports on GBIO shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a report on Thursday, May 8th. Canaccord Genuity Group reissued a “buy” rating and issued a $9.00 target price on shares of Generation Bio in a report on Monday, March 17th. Finally, Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a report on Friday, March 14th. View Our Latest Research Report on Generation Bio Generation Bio Price Performance GBIO stock opened at $0.43 on Wednesday. The business has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.69. Generation Bio Co. has a fifty-two week low of $0.32 and a fifty-two week high of $3.65. The stock has a market capitalization of $28.50 million, a price-to-earnings ratio of -0.19 and a beta of 2.66. Generation Bio (NASDAQ:GBIO – Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $1.70 million. On average, equities analysts expect that Generation Bio Co. will post -1.75 earnings per share for the current fiscal year. About Generation Bio (Free Report) Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D.
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago.
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company.